Drugs / AR-C165395XX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02367066 | Mar → May 2015 | type 2 diabetes mellitus | AstraZeneca | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR-C165395XX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02367066 ↗ |
| Route | Oral | “Oral dose of AR-C165395XX (tablets)” NCT02367066 ↗ |